IgA nephropathy involves deposition of IgA-containing immune complexes in the glomerular mesangium, triggering glomerular inflammation and scarring.
IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide, with an estimated global incidence between 1.4 and 2.5 per 100 000 persons in the US.
Up to 50% of patients with IgA nephropathy develop kidney failure within 10 years of diagnosis, and life expectancy is estimated to be 6 years shorter for those with IgA nephropathy compared with matched controls.
đ This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.
This review discusses the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy (IgAN) in adults, with a focus on treatment recommendations based on the 2025 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for IgAN.







